专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006067466A3 PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS 审中-公开
标题翻译：作为治疗化合物的吡咯并吡啶及其衍生物
公开(公告)号：WO2006067466A3
公开(公告)日：2007-07-05
申请号：PCT/GB2005005011
申请日：2005-12-22
申请人： WELLCOME TRUST LTD , SPRINGER CAROLINE JOY , NICULESCU-DUVAZ ION , ROMAN VELA ESTEBAN , GILL ADRIAN LIAM , TAYLOR RICHARD DAVID , MARAIS RICHARD MALCOLM
发明人： SPRINGER CAROLINE JOY , NICULESCU-DUVAZ ION , ROMAN VELA ESTEBAN , GILL ADRIAN LIAM , TAYLOR RICHARD DAVID , MARAIS RICHARD MALCOLM
IPC分类号： C07D241/20 , A61K31/444 , A61K31/497 , A61P35/00 , C07D213/74 , C07D317/46 , C07D319/18 , C07D321/10 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12
CPC分类号： C07D213/74 , C07D241/20 , C07D317/46 , C07D319/18 , C07D321/10 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The present invention pertains to certain pyrazines and pyridines, and dervatives thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formulae: (I) wherein: Q is independently -N= or -CH=; one of R P2 and R P3 is independently a group of the formula -J 1 -L 1 -Z; wherein: if Q is -N=, then -J 1 -L 1 -Z is independently: -NH-Z; -O-Z; or S-Z; if Q is -CH=, then -J 1 -L 1 -Z is independently: -NH-(CH 2 ) n -Z, wherein n is independently 0 or 1; -O-Z; or -S-Z; Z is independently: C 6-14 carboaryl, C 5-14 heteroaryl, C 3-12 carbocyclic, C 3-12 heterocyclic; and is independently unsubstituted or substituted; the other of R P2 and R P3 is independently -H, -NHR N1 , or -NHC(=O)R N2 ; wherein: R N1 , if present, is independently -H or aliphatic saturated C 1-4 alkyl; R N2 , if present, is independently -H or aliphatic saturated C 1-4 alkyl; one of R P5 and R P6 is independently a group of the formula -W-Y; wherein: W is independently: a covalent bond; -NR N4 -, -O-, -S-, -C(=O)-, -CH 2 -; -NR N4 -CH 2 -, -O-CH 2 -, -S-CH 2 -, -C(=O)-CH 2 -, -(CH 2 ) 2 -; -CH 2 -NR N4 -, -CH 2 -O-, -CH 2 -S-, or -CH 2 -C(=O)-; wherein R N4 , if present, is independently -H or aliphatic saturated C 1-4 alkyl; Y is independently: C 6-14 carboaryl, C 5-14 heteroaryl, C 3-12 carbocyclic, C 3-12 heterocyclic; and is independently unsubstituted or substituted; the other of R P5 and R P6 is independently -H; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, e.g., both in vitro and in vivo, to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.
摘要翻译：本发明涉及某些吡嗪和吡啶及其衍生物，其特别是抑制RAF（例如，B RAF）活性，抑制细胞增殖，治疗癌症等，更具体地涉及下式的化合物：（I ）其中：Q独立地为-N =或-CH =; R“P2”和“R”中的一个独立地是式-I-1-L-1-Z的基团 ; 其中：如果Q是-N =，则-J 1 -L 1 -Z独立地是：-NH-Z; -O-Z; 或S-Z; 如果Q是-CH =，则-J 1 -L 1 -Z独立地是：-NH-（CH 2 CH 2） n -Z，其中n独立地为0或1; -O-Z; 或-S-Z; Z独立地为：C 6-14芳烷基，C 5-14杂芳基，C 3-12碳环，C 3-12 杂环; 并且独立地是未取代的或取代的; R 2 P2和R 3 P 2中的另一个独立地为-H，-NHR 1 N 1或-NHC（= O）R N 2 ; 其中：如果存在，R“独立地为-H或脂族饱和C 1-4烷基; 如果存在，则R 2独立地为-H或脂族饱和C 1-4烷基; R 5 P 5和R 6 P 6中的一个独立地是式-W-Y的基团; 其中：W独立地为：共价键; -NR N - ， - O - ， - S - ， - C（= O） - ， - CH 2 - 。 -NR N4 - CH 2 - ， - O-CH 2 - ， - S-CH 2 - ， - -C（= O）-CH 2 - ， - （CH 2）2 - ; - （CH 2）2 - -CH 2，-NR N 4 - ， - CH 2 -O - ， - CH 2 -S-，或-CH 2 -C（= O） - ; 其中R“N4”（如果存在）独立地是-H或脂族饱和C 1-4烷基; Y独立地为：C 6-14碳芳基，C 5-14杂芳基，C 3-12碳环，C 3-12 杂环基; 并且独立地是未取代的或取代的; R“P5”和“R”P6中的另一个独立地是-H; 酰胺，酯，醚，N-氧化物，化学保护形式及其前体药物。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内两者抑制RAF（例如B-RAF）活性抑制受体酪氨酸激酶（RTK）的用途，活性，抑制细胞增殖，以及通过抑制RAF，RTK等改善增殖条件如癌症（例如结肠直肠癌，黑素瘤）等的疾病和病症的治疗。

2. 发明申请

WO2006067466A2 PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS 审中-公开
标题翻译：作为治疗化合物的吡咯并吡啶及衍生物
公开(公告)号：WO2006067466A2
公开(公告)日：2006-06-29
申请号：PCT/GB2005/005011
申请日：2005-12-22
申请人： THE WELLCOME TRUST LIMITED , SPRINGER, Caroline, Joy , NICULESCU-DUVAZ, Ion , ROMAN VELA, Esteban , GILL, Adrian, Liam , TAYLOR, Richard, David , MARAIS, Richard, Malcolm
发明人： SPRINGER, Caroline, Joy , NICULESCU-DUVAZ, Ion , ROMAN VELA, Esteban , GILL, Adrian, Liam , TAYLOR, Richard, David , MARAIS, Richard, Malcolm
IPC分类号： C07D213/74 , C07D241/20 , C07D317/46 , C07D319/18 , C07D321/10 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12
CPC分类号： C07D213/74 , C07D241/20 , C07D317/46 , C07D319/18 , C07D321/10 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The present invention pertains to certain pyrazines and pyridines, and dervatives thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formulae: (I) wherein: Q is independently -N= or -CH=; one of R P2 and R P3 is independently a group of the formula -J 1 -L 1 -Z; wherein: if Q is -N=, then -J 1 -L 1 -Z is independently: -NH-Z; -O-Z; or S-Z; if Q is -CH=, then -J 1 -L 1 -Z is independently: -NH-(CH 2 ) n -Z, wherein n is independently 0 or 1; -O-Z; or -S-Z; Z is independently: C 6-14 carboaryl, C 5-14 heteroaryl, C 3-12 carbocyclic, C 3-12 heterocyclic; and is independently unsubstituted or substituted; the other of R P2 and R P3 is independently -H, -NHR N1 , or -NHC(=O)R N2 ; wherein: R N1 , if present, is independently -H or aliphatic saturated C 1-4 alkyl; R N2 , if present, is independently -H or aliphatic saturated C 1-4 alkyl; one of R P5 and R P6 is independently a group of the formula -W-Y; wherein: W is independently: a covalent bond; -NR N4 -, -O-, -S-, -C(=O)-, -CH 2 -; -NR N4 -CH 2 -, -O-CH 2 -, -S-CH 2 -, -C(=O)-CH 2 -, -(CH 2 ) 2 -; -CH 2 -NR N4 -, -CH 2 -O-, -CH 2 -S-, or -CH 2 -C(=O)-; wherein R N4 , if present, is independently -H or aliphatic saturated C 1-4 alkyl; Y is independently: C 6-14 carboaryl, C 5-14 heteroaryl, C 3-12 carbocyclic, C 3-12 heterocyclic; and is independently unsubstituted or substituted; the other of R P5 and R P6 is independently -H; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, e.g., both in vitro and in vivo , to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.
摘要翻译：本发明涉及某些吡嗪和吡啶及其衍生物，其特别是抑制RAF（例如，B RAF）活性，抑制细胞增殖，治疗癌症等，更具体地涉及下式的化合物：（I ）其中：Q独立地为-N =或-CH =; R“P2”和“R”中的一个独立地是式-I-1-L-1-Z的基团 ; 其中：如果Q是-N =，则-J 1 -L 1 -Z独立地是：-NH-Z; -O-Z; 或S-Z; 如果Q是-CH =，则-J 1 -L 1 -Z独立地是：-NH-（CH 2 CH 2） n -Z，其中n独立地为0或1; -O-Z; 或-S-Z; Z独立地为：C 6-14芳烷基，C 5-14杂芳基，C 3-12碳环，C 3-12 杂环; 并且独立地是未取代的或取代的; R 2 P2和R 3 P 2中的另一个独立地为-H，-NHR 1 N 1或-NHC（= O）R N 2 ; 其中：如果存在，R“独立地为-H或脂族饱和C 1-4烷基; 如果存在，则R 2独立地为-H或脂族饱和C 1-4烷基; R 5 P 5和R 6 P 6中的一个独立地是式-W-Y的基团; 其中：W独立地为：共价键; -NR N - ， - O - ， - S - ， - C（= O） - ， - CH 2 - 。 -NR N4 - CH 2 - ， - O-CH 2 - ， - S-CH 2 - ， - -C（= O）-CH 2 - ， - （CH 2）2 - ; - （CH 2）2 - -CH 2，-NR N 4 - ， - CH 2 -O - ， - CH 2 -S-，或-CH 2 -C（= O） - ; 其中R“N4”（如果存在）独立地是-H或脂族饱和C 1-4烷基; Y独立地为：C 6-14碳芳基，C 5-14杂芳基，C 3-12碳环，C 3-12 杂环基; 并且独立地是未取代的或取代的; R“P5”和“R”P6中的另一个独立地是-H; 酰胺，酯，醚，N-氧化物，化学保护形式及其前体药物。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内两者抑制RAF（例如B-RAF）活性抑制受体酪氨酸激酶（RTK）的用途，活性，抑制细胞增殖，以及通过抑制RAF，RTK等改善增殖条件如癌症（例如结肠直肠癌，黑素瘤）等的疾病和病症的治疗。

3. 发明申请

WO2006043090A1 IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS 审中-公开
标题翻译：咪唑并[4,5-B]吡啶-2-酮和氧杂唑[4,5-B]吡啶-2-酮化合物及其类似物作为治疗化合物
公开(公告)号：WO2006043090A1
公开(公告)日：2006-04-27
申请号：PCT/GB2005/004081
申请日：2005-10-21
申请人： CANCER RESEARCH TECHNOLOGY LIMITED , INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) , ASTEX THERAPEUTICS LIMITED , NICULESCU-DUVAZ, Dan , SPRINGER, Caroline, Joy , GILL, Adrian, Liam , TAYLOR, Richard, David , MARAIS, Richard, Malcolm , DIJKSTRA, Harmen , GAULON, Catherine , MENARD, Delphine , ROMAN VELA, Esteban
发明人： NICULESCU-DUVAZ, Dan , SPRINGER, Caroline, Joy , GILL, Adrian, Liam , TAYLOR, Richard, David , MARAIS, Richard, Malcolm , DIJKSTRA, Harmen , GAULON, Catherine , MENARD, Delphine , ROMAN VELA, Esteban
IPC分类号： C07D471/04 , C07D498/04 , A61K31/4353 , A61P35/00
CPC分类号： C07D471/04
摘要： The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof, which, inter alia , inhibit RAF (e.g., B-RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formula (I): wherein: J is independently -O- or -NR N1 -; R N1 , if present, is independently -H or a substituent; R N2 is independently -H or a substituent; Y is independently -CH= or -N=; Q is independently -(CH 2 ) j -M-(CH 2 ) k - wherein: j is independently 0, 1 or 2; k is independently 0, 1, or 2; j+k is 0, 1, or 2; M is independently -O-, -S-, -NH-, -NMe-, or -CH 2 -; each of R P1 , R P2 , R P3 , and R P4 is independently -H or a substituent; and additionally R P1 and R P2 taken together may be -CH=CH-CH=CH-; L is independently: a linker group formed by a chain of 2, 3, or 4 linker moieties; each linker moiety is independently -CH 2 -,-NR N -, -C(=X)-, or -S(=O) 2 -; exactly one linker moiety is -NR N -, or: exactly two linker moieties are -NR N -; exactly one linker moiety is -C(=X)-, and no linker moiety is -S(=O) 2 -; or: exactly one linker moiety is -S(=O) 2 -, and no linker moiety is -C(=X)-; no two adjacent linker moieties are -NR N -; X is independently =O or =S; each R N is independently -H or a substituent; A is independently: C 6-14 carboaryl, C 5-14 heteroaryl, C 3-12 carbocyclic, C 3-12 heterocyclic; and is independently unsubstituted or substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo , to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.
摘要翻译：本发明涉及某些咪唑并[4,5-b]吡啶-2-酮和恶唑并[4,5-b]吡啶-2-酮化合物及其类似物，其中i

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式